A year and a half after Sutter Health agreed to a tentative settlement in a closely watched antitrust case, the San Francisco judge presiding over the case indicated she would sign off on the terms, pending agreement on another contentious issue: attorney fees.
With covid cases on the upswing again around the country, partisan division remains over how to address the pandemic. Meanwhile, the Biden administration proposes bigger penalties for hospitals that fail to make their prices public as required. Stephanie Armour of The Wall Street Journal, Alice Miranda Ollstein of Politico and Tami Luhby of CNN join KHN’s Julie Rovner to discuss these issues and more. Also, for “extra credit,” the panelists suggest their favorite stories of the week they think you should read, too.
The July 9 directive addresses the importation of prescription drugs and broader efforts to reduce the high cost of medicines.
Only severely injured patients are supposed to be billed for “trauma team alert” fees that can exceed $50,000.
When patients with common terminal illnesses such as cancer seek permission for compassionate use of therapies in the testing stage, their requests often are approved. But those with more unusual illnesses say drug companies are rarely willing to provide access.
A group of New York senior living facilities offer teens from 10 underserved schools the chance to volunteer and get free training for entry-level health jobs, career coaching and assistance on college prep.
Policies mandating company approval before talking publicly about conditions in hospitals have been a source of conflict over the past year, as physicians, nurses and other health workers have been disciplined for speaking or posting about what they view as dangerous covid-19 safety precautions. The appeals court’s decision could mean that hospitals — and other employers — will need to revise their policies.
The pharmaceutical industry argues that large profits are needed to fund extensive research and innovation. But Democrats on the House Oversight and Reform Committee, seeking to bolster their effort to let Medicare negotiate drug prices, say major drug companies plow more of their billions in earnings back into propping up their stock and enriching executives and shareholders.
Your dutiful columnist tried to make use of a federal “transparency” rule to compare the prices of common medical procedures in two California health care systems. It was a futile exercise.
The Biden administration is moving to undo many of the changes the Trump administration made to the enrollment process for the Affordable Care Act, in an effort to encourage more people to sign up for health insurance. Meanwhile, Congress is opening investigations into the controversial approval by the Food and Drug Administration of an expensive new drug that might or might not slow the progression of Alzheimer’s disease. Joanne Kenen of Politico, Kimberly Leonard of Insider and Sarah Karlin-Smith of The Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Marshall Allen of ProPublica about his new book, “Never Pay the First Bill: And Other Ways to Fight the Health Care System and Win.”
